930-85-8

Usage

Uses

Used in Pharmaceutical Research:
3-Amino-4-iodo-5-methylisoxazole is utilized as a key building block in the development of pharmaceutical compounds. Its unique structure allows it to be incorporated into the design of new drugs and bioactive molecules, potentially leading to the creation of innovative therapeutic agents.
Used in Organic Synthesis:
In the field of organic synthesis, 3-Amino-4-iodo-5-methylisoxazole plays a crucial role as a synthetic intermediate. Its reactivity and functional groups make it a valuable component in the synthesis of complex organic molecules and advanced materials.
Used in Agrochemical Development:
3-Amino-4-iodo-5-methylisoxazole also finds application in the agrochemical industry. It can be used in the preparation of various agrochemicals, contributing to the development of new pesticides, herbicides, and other agricultural chemicals that can improve crop protection and yield.
Due to its potential applications in the development of new drugs, bioactive molecules, and agrochemicals, 3-Amino-4-iodo-5-methylisoxazole is a compound of significant interest to researchers and chemists in various scientific and industrial fields.

Upstream product

• 1072-67-9 5-methylisoxazol-3-ylamine 

Downstream Products

• 6455-42-1 N-(4-iodo-5-methyl-isoxazol-3-yl)-benzamide 
• 6453-54-9 (4-iodo-5-methyl-isoxazol-3-yl)-bis-(4-nitro-benzenesulfonyl)-amine 
• 6453-55-0 N-(4-iodo-5-methyl-isoxazol-3-yl)-4-nitro-benzenesulfonamide 
• 6455-23-8 (4-iodo-5-methyl-isoxazol-3-yl)-bis-(toluene-4-sulfonyl)-amine 
• 6455-24-9 N-(4-iodo-5-methyl-isoxazol-3-yl)-toluene-4-sulfonamide 
• 6455-26-1 N,N'-bis-(4-iodo-5-methyl-isoxazol-3-yl)-4,4'-diazenediyl-bis-benzenesulfonamide 
• 6455-25-0 6,13-bis-(4-iodo-5-methyl-isoxazol-3-yl)-5,7,12,14-tetrathia-2,3,6,9,10,13-hexaaza-1,4,8,11(1,4)-tetrabenzena-cyclotetradecaphane-2,9-diene 5,5,7,7,12,12,14,14-octaoxide 

Relevant academic research and scientific papers

Energetic and topological approach for characterization of supramolecular clusters in organic crystals

In this work, an approach is proposed for understanding the crystal arrangements of organic compounds. The crystals are studied taking into account the stabilization energy and the topological properties like contact surfaces of a molecule (M1) due to the presence of neighboring Mn (cluster). The molecular system models chosen were five heterocycles and one β-enaminone. The cluster of compounds had a Molecular Coordination Number (MCN) of 14, except for one compound that had an MCN of 16. Our study showed that intermolecular interactions can be divided into four main types: type I, with large energy values and a small contact surface; type II, involving a large value for both the energy and the contact surface; type III, with small and medium energy values, and a medium-sized contact surface; and type IV, with small energy values and a relatively large contact surface. Additionally, from this approach we show that only from the supramolecular cluster is it possible to observe the participation of the topological component during the formation of the crystal. This is demonstrated by the fact that the fragility of the electrostatic interaction between M1 and one Mn in the same plane is compensated by a strong interaction of M1 with a molecule in another plane.

Proposal for crystallization of 3-amino-4-halo-5-methylisoxazoles: An energetic and topological approach

The supramolecular structure of 3-amino-4-halo-5-methylisoxazoles (halo = Cl, Br, and I) was investigated in order to suggest a route for crystallization of small molecules. The hierarchy of intermolecular interactions during the growth of the crystal was established by X-ray diffraction, 1H NMR titration, QTAIM analysis and quantum mechanical calculations. The relationship between QTAIM and energetic data was the fundamental innovation in this work. It allowed partitioning of the dimer interaction energy between interacting atoms. The partitioning shows the cooperation of the intermolecular interactions in the stabilization of the dimers and led to observation of the energetic consequences that small changes in the molecular structure of each compound may have on the crystal packing. The proposed route for the crystallization of the supramolecular cluster was based on the energetic hierarchy, in which the hydrogen bond is the strongest interaction and the first to form, and the π-interactions are weaker than the hydrogen bond and cannot compete with it. However, the π-interactions are responsible for the growth of the crystal, connecting the rising layers of the hydrogen bond dimers. The other interaction formed, the halogen bond, is too weak to compete with the other two interactions, but it is fundamental for linking the layer that leads to the final three-dimensional arrangement. Finally, a new way of understanding the crystallization process and the design of new materials is presented.

N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin

N-(4-halo-isoxazolyl)sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(4-halo-3-isoxazolyl)sulfonamides and N-(4-halo-5-isoxazolyl)benzenesulfonamides and methods for inhibiting the binding of an endothelin peptide to an endothelin receptor or increasing the activity of endothelin peptides by contacting the receptor with a sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.

SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN

Sulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided. The sulfonamides have formula I: STR1 in which Ar 1 is a 3-or 5-isoxazolyl and Ar. sup.2 is selected from among alkyl, including straight and branched chains, aromatic rings, fused aromatic rings and heterocyclic rings, including 5-membered heterocycles with one, two or more heteroatoms and fused ring analogs thereof and 6-membered rings with one, two or more heteroatoms and fused ring analogs thereof. Ar 2 is preferably thiophenyl, furyl, pyrrolyl, naphthyl, and phenyl. Compounds in which Ar. sup.1 is a 4-halo-substituted isoxazole are more active than the corresponding alkyl-substituted compound and compounds in which Ar 1 is substituted at this position with a higher alkyl tend to exhibit greater affinity for ET B receptors than the corresponding lower alkyl-substituted compound.